Table 2.
Clinical association between KLK11 and the clinico-pathological factors of patients with mCRC
| Variables | KLK11 expression
|
P-value | |
|---|---|---|---|
| − to +
|
++ to +++
|
||
| (n=23) | (n=32) | ||
| Gender (%) | 1 | ||
| Male | 13 (56.5) | 18 (56.2) | |
| Female | 10 (43.5) | 14 (43.8) | |
| Age (mean ± SD, years) | 52.9±8.8 | 52.7±10.9 | 0.944 |
| ASA score (%) | 0.892 | ||
| 1 | 13 (56.5) | 20 (62.5) | |
| 2 | 7 (30.4) | 8 (25) | |
| 3 | 3 (13.1) | 4 (12.5) | |
| Tumor location (%) | 0.719 | ||
| Sigmoid | 12 (52.2) | 19 (59.4) | |
| Ascending colon | 5 (21.8) | 5 (15.6) | |
| Transverse colon | 3 (13) | 2 (6.2) | |
| Descending colon | 3 (13) | 6 (18.8) | |
| Gross type (%) | 0.996 | ||
| Expanding | 12 (52.2) | 17 (53.1) | |
| Ulcerating | 6 (26.1) | 8 (25) | |
| Infiltrating | 5 (21.7) | 7 (21.9) | |
| Histopathology (%) | 0.004 | ||
| Adenocarcinoma | 22 (95.7) | 19 (59.4) | |
| Mucinous or signet-ring adenocarcinoma | 1 (4.3) | 13 (40.6) | |
| Tumor differentiation (%) | 0.150 | ||
| Well to moderately differentiated | 18 (78.3) | 18 (56.2) | |
| Poorly differentiated and othersa | 5 (21.7) | 14 (43.8) | |
| Pathological T stage (%) | 0.099 | ||
| T1 + T2 | 5 (21.7) | 2 (6.2) | |
| T3 + T4 | 18 (78.3) | 30 (93.8) | |
| Pathological N stage (%) | 0.002 | ||
| N0 | 10 (43.5) | 2 (6.2) | |
| N+ | 13 (56.5) | 30 (93.8) | |
| Pretreatment CEA level (%) | 0.467 | ||
| <5 ng/mL | 5 (21.7) | 4 (12.5) | |
| ≥5 ng/mL | 18 (78.3) | 28 (87.5) | |
| Metastasis (%) | 0.219 | ||
| Single | 22 (95.7) | 26 (81.2) | |
| Multiple | 1 (4.3) | 6 (18.8) | |
Note:
a
Including mucinous or signet-ring adenocarcinoma.
Abbreviations: KLK11, kallikrein11; ASA, American Society of Anesthesiologists; CEA, carcinoembryonic antigen; mCRC, metastatic colorectal cancer.